Potentially curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases were developed by Intellia Therapeutics. This company is spinoff of Harvard University. Intellia Therapeutics is focused on positively disrupting health care treatment of patients with genomic diseases. Conventional medicines treat the symptoms instead of the genetic cause of severe and life-threatening diseases, meaning that patients must take these therapies throughout their lives. Intellia is revolutionizing medicine by harnessing the power of genome editing to develop potential cures. They bring new hope for people living with conditions including cancer (lat. Carcinoma), genetic disorders, viral infections, inflammatory disorders and many more.